These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22874478)

  • 1. Viral load monitoring in resource-limited settings: a medical and public health priority.
    Ford N; Roberts T; Calmy A
    AIDS; 2012 Aug; 26(13):1719-20. PubMed ID: 22874478
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings.
    Schneider K; Puthanakit T; Kerr S; Law MG; Cooper DA; Donovan B; Phanuphak N; Sirisanthana V; Ananworanich J; Ohata J; Wilson DP
    AIDS; 2011 Jun; 25(9):1143-51. PubMed ID: 21505319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world.
    Tucker T; Yeats J
    S Afr Med J; 2001 Aug; 91(8):615. PubMed ID: 11584766
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-1 viral load testing cost in developing countries: what's new?
    Rouet F; Rouzioux C
    Expert Rev Mol Diagn; 2007 Nov; 7(6):703-7. PubMed ID: 18020900
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings.
    Lynen L; Van Griensven J; Elliott J
    Curr Opin HIV AIDS; 2010 Jan; 5(1):1-5. PubMed ID: 20046141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The measurement of HIV-1 viral load in resource-limited settings: how and where?
    Rouet F; Rouzioux C
    Clin Lab; 2007; 53(3-4):135-48. PubMed ID: 17447649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral load testing in resource-limited settings.
    Schooley RT
    Clin Infect Dis; 2007 Jan; 44(1):139-40. PubMed ID: 17143830
    [No Abstract]   [Full Text] [Related]  

  • 8. Universal access to HIV treatment in developing countries: going beyond the misinterpretations of the 'cost-effectiveness' algorithm.
    Moatti JP; Marlink R; Luchini S; Kazatchkine M
    AIDS; 2008 Jul; 22 Suppl 1():S59-66. PubMed ID: 18664955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV resistance and the developing world.
    Gupta RK; Pillay D
    Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV viral load monitoring in resource-limited regions: optional or necessary?
    Calmy A; Ford N; Hirschel B; Reynolds SJ; Lynen L; Goemaere E; Garcia de la Vega F; Perrin L; Rodriguez W
    Clin Infect Dis; 2007 Jan; 44(1):128-34. PubMed ID: 17143828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.
    Moatti JP; N'Doye I; Hammer SM; Hale P; Kazatchkine M
    Nat Med; 2003 Dec; 9(12):1449-52. PubMed ID: 14647513
    [No Abstract]   [Full Text] [Related]  

  • 12. Health care industries' perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay.
    Elbeik T; Loftus RA; Beringer S
    Expert Rev Mol Diagn; 2002 May; 2(3):275-85. PubMed ID: 12050866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.
    Ivers LC; Kendrick D; Doucette K
    Clin Infect Dis; 2005 Jul; 41(2):217-24. PubMed ID: 15983918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health. Global HIV/AIDS policy in transition.
    Bongaarts J; Over M
    Science; 2010 Jun; 328(5984):1359-60. PubMed ID: 20538936
    [No Abstract]   [Full Text] [Related]  

  • 15. The cost effectiveness of antiretroviral therapy for HIV disease.
    Laurence J
    N Engl J Med; 2001 Jul; 345(1):68; author reply 68-9. PubMed ID: 11439961
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world?
    Lawn SD; Myer L; Wood R
    Clin Infect Dis; 2005 Dec; 41(11):1683-4; author reply 1684. PubMed ID: 16267745
    [No Abstract]   [Full Text] [Related]  

  • 17. First-line antiretroviral therapy in resource-limited settings: time to reconsider?
    Adlington R; Richens J; Shahmanesh M
    J Infect Dis; 2009 May; 199(9):1407; author reply 1407-8. PubMed ID: 19358673
    [No Abstract]   [Full Text] [Related]  

  • 18. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda.
    Kent DM; McGrath D; Ioannidis JP; Bennish ML
    Clin Infect Dis; 2003 Jul; 37(Suppl 1):S13-24. PubMed ID: 12822128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.
    Gerlach J; Sequeira M; Alvarado V; Cerpas C; Balmaseda A; Gonzalez A; de Los Santos T; Levin CE; Amador JJ; Domingo GJ
    J Int AIDS Soc; 2010 Nov; 13():43. PubMed ID: 21054866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries.
    Maponga CC; Ma Q; Slish JC; Morse GD
    Top HIV Med; 2007; 15(3):104-10. PubMed ID: 17598930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.